OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trialPeter Nash, Aelion Ja, Duc Thanh Nguyen et al.|Annals of the Rheumatic Diseases|2017Cited by 3
SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trialArthur Kavanaugh, J. Wollenhaupt, Gladman Dd et al.|Annals of the Rheumatic Diseases|2017Cited by 0